Independent Equity Research Analyst
I have worked in the investment industry since 1986 and earned the CFA charter in 1997. I worked for Kidder, Peabody in bonds from 1986-1992 and then First Boston's investment management subsidiary from 1992-1994, both in NYC. I then joined Criterion Investment Management (later acquired by ...more

ALL CONTRIBUTIONS

Comments

Latest Comments
OGI: My Favorite Canadian LP
58 minutes ago
I think that the company is doing just fine. It's hard to tell who will hold up in a downturn. I have watched them work their way out of a big problem over time, the pesticide issue that brought in Greg Engel to be CEO, and I feel like they are big enough and have a balance sheet and a strategic partner that would help them weather any storms.
In this article: OGI
OGI: My Favorite Canadian LP
2 hours ago
The one I used, EV/EBITDA,
In this article: OGI
OGI: My Favorite Canadian LP
2 hours ago
This is a good question and am important topic in my view. The good news is that the acquisition closed last December, so after this upcoming report next month for Q1, which will have a full quarter with Motif compared to a partial revenue quarter last year, the Motif revenue will be fully organic for the last three quarters. In FY25-Q1, Motif contributed just C$$7.8 million of gross revenue. The filings from Q4 indicate that Motif total revenue on a gross basis for FY25-Q1 would have been C$38.9 million, including the 10 weeks prior to the acquisition closing. I am not trying to predict the exact amount from Motif Labs for Q1, but a good guess is C$46.8 million. Thus, the inorganic growth in Q1 of gross revenue will be C$39 million. This works out to 58% for Q1 or about 10% for the year.
In this article: OGI
OGI: My Favorite Canadian LP
2 hours ago
Thanks for commenting! I do see a lot of risks, as well as some opportunities. The biggest risk in my view, but not the only one, is Canada tanking, as that is where a lot of its business takes place. The Canadian cannabis market is mature and has been slowing. Cannabis historically has been viewed as like a Consumer Staples product, immune to economic weakness, but that is when it is medical in nature. If the Canadian economy is very weak, it could hurt revenue for OGI.
In this article: OGI
1 to 4 of 4 comments

STOCKS I FOLLOW

TWEETS

PERSONAL BLOG

Latest Posts

Work Experience

Education

Publications